Safety evaluation of calcium L-methylfolate

K E Niederberger, I Dahms, T H Broschard, R Boehni, R Moser, K E Niederberger, I Dahms, T H Broschard, R Boehni, R Moser

Abstract

Calcium L-methylfolate (L-5-MTHF-Ca; CAS Number 151533-22-1) is a source of folate and an alternative to folic acid for use in human food and food supplements. The safety of L-5-MTHF-Ca was evaluated by testing for genotoxicity, subchronic and prenatal developmental toxicity. In in vitro assays L-5-MTHF-Ca was not mutagenic and did not induce other chromosomal events. Additionally, L-5-MTHF-Ca was not genotoxic in the in vivo micronucleus test nor did it induce DNA damage in rat liver cells. In a subchronic toxicity study, rats administered up to 400 mg/kg bw/day of L-5-MTHF-Ca via oral gavage for 13 weeks had no treatment-related mortalities, and no treatment-related effects were identified on behaviour, body weight, food consumption, ophthalmology, haematology, or organ weights. No treatment-related macroscopic or histopathological findings were observed. Calcium and sodium levels increased with increasing dosage, however the slight increases were within historical control ranges and reversible after the recovery period. L-5-MTHF-Ca is neither teratogenic nor embryotoxic. Based on the results of the in vitro and in vivo studies, the safe use of L-5-MTHF-Ca as an ingredient in foods is supported. The no observed adverse effect level was the highest dose in the subchronic toxicity study, i.e. 400 mg/kg bw/day for male and female rats.

Keywords: 5-MTHF, 5-methyltetrahydrofolate; ANOVA, analysis of variance; BaP, benzo[a]pyrene; Calcium L-methylfolate; Developmental toxicity; EFSA, European Food Safety Authority; GD, gestation day; GLP, Good Laboratory Practice; GRAS, generally recognized as safe; Genotoxicity; HPLC, High Performance Liquid Chromatography; JECFA, Joint FAO/WHO Expert Committee on Food Additives; L-5-MTHF-Ca; L-5-MTHF-Ca, calcium L-methylfolate; MTT, 3-[45-dimethylthiazole-2-yl]-2,5-diphenylbromide; NNG, net grains/nucleus; NOAEL, No Observed Adverse Effect Level; OECD, Organisation for Economic Co-operation and Development; TFT, 5-trifluorothymidine; Toxicity; USP, United States Pharmacopeia; WE-I, Williams E medium-Incomplete; bw, body weight.

Conflict of interest statement

The authors declare no conflict of interest.

© 2019 The Authors.

References

    1. Bailey L.B., Gregory J.F. Folate metabolism and requirements. J. Nutr. 1999;129:779–782.
    1. Shrubsole M.J., Jin F., Dai Q., Shu X.O., Potter J.D., Hebert J.R., Gao Y.T., Zheng W. Dietary folate intake and breast cancer risk: results from the Shanghai Breast Cancer Study. Cancer Res. 2001;61:7136–7141.
    1. Robinson K., Arheart K., Refsum H., Brattström L., Boers G., Ueland P., Rubba P., Palma-Reis R., Meleady R., Daly L., Witteman J., Graham I. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation. 1998;97:437–443.
    1. Laurence K.M., James N., Miller M.H., Tennant G.B., Campbell H. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. Br. Med. J. (Clin. Res. Ed.) 1981;282:1509–1511.
    1. Witthöft C.M., Forssén K., Johannesson L., Jägerstad M. Folates - food sources, analyses, retention and bioavailability. Näringsforskning. 1999;43:138–146.
    1. Scott J. Methyltetrahydrofolate: the superior alternative to folic acid. In: Krämer K., Hoppe P.-P., Packer L., editors. Nutraceuticals in Health and Disease Prevention. Dekker; New York: 2001. pp. 75–90.
    1. Page R., Robichaud A., Arbuckle T.E., Fraser W.D., MacFarlane A.J. Total folate and unmetabolized folic acid in the breast milk of a cross-section of Canadian women. Am. J. Clin. Nutr. 2017;105:1101–1109.
    1. Büttner B.E., Witthöft C.M., Domellöf M., Hernell O., Öhlund I. Effect of type of heat treatment of breastmilk on folate content and pattern. Breastfeed. Med. 2014;9:86–91.
    1. Sherwood K.L., Houghton L.A., Tarasuk V., O’Connor D.L. One-third of pregnant and lactating women may not be meeting their folate requirements from diet alone based on mandated levels of folic acid fortification. J. Nutr. 2006;136:2820–2826.
    1. Lewis C.J., Crane N.T., Wilson D.B., Yetley E.A. Estimated folate intakes: data updated to reflect food fortification, increased bioavailability, and dietary supplement use. Am. J. Clin. Nutr. 1999;70:198–207.
    1. Konings E.J., Roomans H.H., Dorant E., Goldbohm R.A., Saris W.H., van den Brandt P.A. Folate intake of the Dutch population according to newly established liquid chromatography data for foods. Am. J. Clin. Nutr. 2001;73:765–776.
    1. Troen A.M., Mitchell B., Sorensen B., Wener M.H., Johnston A., Wood B., Selhub J., McTiernan A., Yasui Y., Oral E., Potter J.D., Ulrich C.M. Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women. J. Nutr. 2006;136:189–194.
    1. Kelly P., McPartlin J., Goggins M., Weir D.G., Scott J.M. Unmetabolized folic acid in serum: acute studies in subjects consuming fortified food and supplements. Am. J. Clin. Nutr. 1997;65:1790–1795.
    1. Wilcken B., Bamforth F., Li Z., Zhu H., Ritvanen A., Renlund M., Stoll C., Alembik Y., Dott B., Czeizel A.E., Gelman-Kohan Z., Scarano G., Bianca S., Ettore G., Tenconi R., Bellato S., Scala I., Mutchinick O.M., López M.A., de Walle H., Hofstra R., Joutchenko L., Kavteladze L., Bermejo E., Martínez-Frías M.L., Gallagher M., Erickson J.D., Vollset S.E., Mastroiacovo P., Andria G., Botto L.D., Redlund M. Geographical and ethnic variation of the 677CT allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J. Med. Genet. 2003;40:619–625.
    1. Botto L.D., Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am. J. Epidemiol. 2000;151:862–877.
    1. McCaddon A., Hudson P.R. L-methylfolate, methylcobalamin, and N-acetylcysteine in the treatment of Alzheimer’s disease-related cognitive decline. CNS Spectr. 2010;15:2–5. discussion 6.
    1. Zajecka J.M., Fava M., Shelton R.C., Barrentine L.W., Young P., Papakostas G.I. Long-term efficacy, safety, and tolerability of L-methylfolate calcium 15 mg as adjunctive therapy with selective serotonin reuptake inhibitors: a 12-month, open-label study following a placebo-controlled acute study. J. Clin. Psychiatry. 2016;77:654–660.
    1. Rainka M., Aladeen T., Westphal E., Meaney J., Gengo F., Capote H. L-Methylfolate calcium in adolescents and children: a retrospective analysis (P5.337) Neurology. 2018;90:P5.337.
    1. Utesch D., Glatt H., Oesch F. Rat hepatocyte-mediated bacterial mutagenicity in relation to the carcinogenic potency of benz(a)anthracene, benzo(a)pyrene, and twenty-five methylated derivatives. Cancer Res. 1987;47:1509–1515.
    1. Maron D.M., Ames B.N. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 1983;113:173–215.
    1. Green M.H.L., Muriel W.J. Mutagen testing using TRP+ reversion in Escherichia coli. Mutat. Res. 1976;38:3–32.
    1. Ames B.N., McCann J., Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat. Res. 1975;31:347–363.
    1. Cole J., Arlett C.F., Green M.H.L., Lowe J., Muriel W. A comparison of the agar cloning and microtitration techniques for assaying cell survival and mutation frequency in L5178Y mouse lymphoma cells. Mutat. Res. 1983;111:371–386.
    1. Schmid W. The micronucleus test. Mutat. Res. 1975;31:9–15.
    1. Romagna F. Series: Current issues in mutagenesis and carcinogenesis. Mutat. Res. 1988;206:307–309.
    1. Gollapudi B., Kamra O.P. Application of a simple Giemsa-staining method in the micronucleus test. Mutat. Res. 1979;64:45–46.
    1. Kennelly J.C., Waters R., Ashby J., Lefevre P.A., Burlinson B., Benford D.J., Dean S.W., Mitchell Id.G. In vivo rat liver UDS assay. In: Kirkland D.J., Fox M., Brooks T.M., editors. Supplementary Mutagenicity Tests: UKEMS Recommended Procedures / UKEMS Subcommittee on Guidelines for Mutagenicity Testing, Report, Part II Revised. Cambridge University Press; Cambridge: 1993. pp. 52–77.
    1. FDA . 1998. New Dietary Ingredient 23 - Methyltetrahydrofolate (5-MTHF) – Supporting & Related Materials. ID: FDA-1998-S-1294-0025 ( ). Accessed 4 July 2019.
    1. Barrow M.V., Taylor W.J. A rapid method for detecting malformations in rat fetuses. J. Morphol. 1969;127:291–305.
    1. Wilson J.G. Embryological considerations in teratology. Methods for administering agents and detecting, alformations in experimental animals. In: Wilson J.G., Warkany J., editors. Teratology. Principles and Techniques. (Lectures and Demonstrations Given at the First Workshop in Teratology, University of Florida, February 2-8, 1964.) University of Chicago Press; 1965. pp. 251–277.
    1. Whitaker J., Dix K.M. Double staining technique for rat foetus skeletons in teratological studies. Lab Anim. 1979;13:309–310.
    1. Holm S. A simple sequentially rejective multiple test procedure. Scand. J. Stat. 1979:65–70.
    1. Kier L.D., Brusick D.J., Auletta A.E., von Halle E.S., Brown M.M., Simmon V.F., Dunkel V., McCann J., Mortelmans K., Kier L.E. The Salmonella typhimurium/mammalian microsomal assay. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat. Res. 1986;168:69–240.
    1. Levin D.E., Hollstein M., Christman M.F., Schwiers E.A., Ames B.N. A new Salmonella tester strain (TA102) with A X t base pairs at the site of mutation detects oxidative mutagens. Proc. Natl. Acad. Sci. U. S. A. 1982;79:7445–7449.
    1. Hashimoto S., Doi T., Wako Y., Sato J., Wada S., Tsuchitani M. Corneal mineralization in wistar hannover rats. J. Toxicol. Pathol. 2013;26:275–281.
    1. Chacaltana F.D.Y.C., Kobashigawa K.K., Padua I.R.M., Valdetaro G.P., Aldrovani M., Laus J.L. Persistent papillary membrane in Wistar laboratory rats (Rattus Norvegicus, Albinus Variation, Wistar) Cienc. Rural. 2017;47:204.
    1. EFSA Opinion of the Scientific Panel on food additives, flavourings, processing aids and materials in contact with food (AFC) related to Calcium L-Methylfolate. EFSA J. 2004;2:135.
    1. Perna A.F., Ingrosso D., de Santo N.G., Galletti P., Brunone M., Zappia V. Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia. J. Am. Soc. Nephrol. 1997;8:1899–1905.
    1. Ambrosino P., Lupoli R., Di Minno A., Nardo A., Marrone E., Lupoli V., Scaravilli A., Mitidieri E., Tufano A., Di Minno M.N.D. Cyclic supplementation of 5-MTHF is effective for the correction of hyperhomocysteinemia. Nutr. Res. 2015;35:489–495.
    1. Pentieva K., McNulty H., Reichert R., Ward M., Strain J.J., McKillop D.J., McPartlin J.M., Connolly E., Molloy A., Krämer K., Scott J.M. The short-term bioavailabilities of 6S-5-methyltetrahydrofolate and folic acid are equivalent in men. J. Nutr. 2004;134:580–585.
    1. Lamers Y., Prinz-Langenohl R., Brämswig S., Pietrzik K. Red blood cell folate concentrations increase more after supplementation with 6S-5-methyltetrahydrofolate than with folic acid in women of childbearing age. Am. J. Clin. Nutr. 2006;84:156–161.
    1. de Meer K., Dainty J.R., Finglas P.M., Jakobs C., Kok R.M., Smith D.E.C., Smulders Y.M., Stehouwer C.D.A. 6S 5-methyltetrahydrofolate or folic acid supplementation and absorption and initial elimination of folate in young and middle-aged adults. Eur. J. Clin. Nutr. 2005;59:1409–1416.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する